Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Medtronic plc (NYSE:MDT) has resolved a warning letter from the FDA regarding its Diabetes headquarters in Northridge, California, which was received in December 2021. The FDA's decision comes shortly after the agency approved the MiniMed™ 780G system, the first automated insulin delivery system with real-time meal detection technology. The new system adjusts glucose levels automatically every five minutes, addressing significant needs in diabetes management. Medtronic expresses gratitude for the collaborative efforts with the FDA, which enable the company to focus on delivering innovative solutions for diabetes patients. This resolution marks a crucial step for Medtronic's Diabetes division, ensuring adherence to quality standards and paving the way for future advancements.
Medtronic plc (NYSE: MDT) announced FDA approval for its MiniMed™ 780G system with Guardian™ 4 sensor, the first insulin pump featuring meal detection technology. This device delivers automatic adjustments to insulin every 5 minutes, addressing challenges faced by individuals with type 1 diabetes during mealtimes. It offers the lowest glucose target setting of any automated insulin pump, enhancing user experience with 94% of users expressing satisfaction. Clinical trials indicate users achieved a 75% Time in Range for blood sugar levels. Pre-orders will begin on May 15, 2023, and existing MiniMed™ 770G customers can upgrade at no cost.
Medtronic highlights its partnership with Springfield Spring and Stamping, a certified minority-owned business, emphasizing the importance of supplier diversity. This collaboration is a crucial component of Springfield's growth, enabling it to invest in advanced manufacturing technologies. The partnership not only benefits Springfield's business but also contributes to creating well-paying jobs and strengthening the local community. Springfield Spring's owner, Norman Rodrigues, noted that Medtronic's support has been foundational for their company's success, fostering sustainable wealth and economic security for employees. This initiative reflects Medtronic's commitment to community impact and economic development through responsible sourcing.
Medtronic LABS is expanding its scope to address comprehensive community health needs rather than focusing solely on specific diseases. Acknowledging that over 5 billion people lack access to healthcare, the organization aims to enhance healthcare delivery across various conditions including hypertension, diabetes, mental health, and more.
With its technology platform SPICE, LABS has reached over 1 million patients and trained more than 6,500 health workers globally. The initiative is set to grow further with new partnerships, potentially amplifying its impact 10 times over the next few years.
Volunteer Appreciation Month is celebrated every April, recognizing the impact of volunteers and encouraging ongoing volunteerism. The Medtronic Foundation supports communities through resources that enhance volunteer efforts. Marcus Reid, a 30-year Medtronic employee, initiated a grassroots project to teach young probationers their strengths through skills-based volunteering. This initiative has gained traction, with the District Attorney's office requesting training for their staff. Reid's program helps individuals like James, a 20-year-old probationer, to develop self-esteem and explore educational opportunities. The Medtronic Foundation also offers volunteer grants and matching programs to further encourage employee involvement in community support.
Medtronic and DaVita have launched Mozarc Medical, an independent kidney health technology company aimed at enhancing patient care. Announced on April 1, 2023, Mozarc Medical will leverage expertise from Medtronic's former Renal Care Solutions unit and DaVita's leadership to innovate in kidney health technologies. CEO Ven Manda emphasized the need for patient-centered solutions, particularly as demand for in-home kidney care rises. Both companies hold equal equity stakes in Mozarc Medical, which had combined revenues of $64 million, $63 million, and $70 million in the first three quarters of Medtronic's fiscal year 2023.